Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients

Rheumatology (Oxford). 2020 Oct 1;59(10):3058-3069. doi: 10.1093/rheumatology/keaa176.

Abstract

Objectives: To elucidate the molecular mechanisms underlying pathogenic Th17 cells, we investigated the modulation of epigenetic modifications and its association with SLE.

Methods: Naive CD4+ T cells were cultured in Th17 polarizing conditions for 5 days and then treated with various cytokines, including IL-23. Expression of Th17 cell-related markers and phosphorylation of signal transducers and activators of transcription (pSTATs) were analysed using flow cytometry and quantitative PCR. Histone modifications were assessed using chromatin immunoprecipitation PCR. T cell phenotypes and pSTATs were analysed in blood samples of patients with SLE (n = 28). Finally, the effects of baricitinib on memory Th17 cells were investigated in SLE patients (n = 12).

Results: Stimulation of resting Th17 cells with IL-23 promoted maturation of these cells (P < 0.0001). IL-23 induced pSTAT3, but not pSTAT4, during Th17 cell maturation (P < 0.05). IL-23-induced STAT3 directly bound the RORγT gene locus. This was accompanied by induction of the H3H4me3 permissive mark and reduction of the H3K27me3 repressive mark, leading to enhanced RORγT gene expression. IL-23-induced expansion of Th17 cells and pSTAT3 were suppressed by the addition of baricitinib in a concentration-dependent manner (P < 0.05). In memory Th17 cells from SLE patients, pSTAT3 was hypersensitized by IL-23 stimulation and inhibited by baricitinib (P < 0.05).

Conclusion: The results of this study indicate that IL-23/STAT3 signalling plays a fundamental role in Th17 cell maturation through transcriptional and epigenetic modifications in patients with SLE. This mechanism may underlie pathogenic Th17 cell expansion and may lead to identification of novel therapeutic targets for SLE.

Keywords: IL-23; Th17 cells; baricitinib; signal transducer and activator of transcription; systemic lupus erythematosus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azetidines / pharmacology
  • CD4-Positive T-Lymphocytes / drug effects
  • Cell Proliferation / drug effects
  • Chromatin Immunoprecipitation / methods
  • Epigenesis, Genetic
  • Flow Cytometry
  • Gene Expression
  • Humans
  • Interleukin-12 / pharmacology
  • Interleukin-21
  • Interleukin-23 / pharmacology*
  • Interleukins / pharmacology
  • Jumonji Domain-Containing Histone Demethylases / metabolism
  • Lupus Erythematosus, Systemic / blood*
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / genetics
  • Nuclear Receptor Subfamily 1, Group F, Member 3 / metabolism
  • Phosphorylation
  • Purines / pharmacology
  • Pyrazoles / pharmacology
  • Real-Time Polymerase Chain Reaction / methods
  • STAT3 Transcription Factor / blood*
  • STAT3 Transcription Factor / drug effects
  • STAT3 Transcription Factor / metabolism
  • STAT4 Transcription Factor / metabolism
  • Signal Transduction
  • Sulfonamides / pharmacology
  • Th17 Cells / drug effects*
  • Th17 Cells / metabolism

Substances

  • Azetidines
  • Interleukin-23
  • Interleukins
  • Nuclear Receptor Subfamily 1, Group F, Member 3
  • Purines
  • Pyrazoles
  • RORC protein, human
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • STAT4 Transcription Factor
  • STAT4 protein, human
  • Sulfonamides
  • Interleukin-12
  • Jumonji Domain-Containing Histone Demethylases
  • baricitinib
  • Interleukin-21